Trial reportBMC pregnancy and childbirth2020
Does growth hormone supplementation improve oocyte competence and IVF outcomes in patients with poor embryonic development? A randomized controlled trial.
Trial report in BMC pregnancy and childbirth, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Growth hormone improves the pregnancy outcomes in poor ovarian responders undergoing in vitro fertilization: an umbrella review.Journal of assisted reproduction and genetics · 2025Pooled it
- Growth hormone for in vitro fertilisation (IVF).The Cochrane database of systematic reviews · 2021Pooled it
- Exploring the potential benefits of growth hormone co-treatment on embryo quality in IVF: a randomized controlled open-label trial.Reproductive biology and endocrinology : RB&E · 2025Trial
- [Growth hormone and fertility: molecular mechanisms and experience of adjuvant therapy in reproductology].Problemy endokrinologii · 2026Review
- The effect of growth hormone on the euploid rate of blastocysts in patients with advanced maternal age: study protocol for a single-blinded randomized controlled trial.BMC pregnancy and childbirth · 2026Article
- Mitochondrial dysfunction in oocytes: implications for fertility and ageing.Journal of ovarian research · 2025Review
- The role of growth hormone in assisted reproductive technology for patients with diminished ovarian reserve: from signaling pathways to clinical applications.Frontiers in endocrinology · 2025Review
- Novel perspectives on growth hormone regulation of ovarian function: mechanisms, formulations, and therapeutic applications.Frontiers in endocrinology · 2025Review
- Does growth hormone supplementation of in vitro fertilization/intracytoplasmic sperm injection improve cumulative live birth rates in women with poor embryonic development in the previous cycle?Reproductive biology and endocrinology : RB&E · 2024Article
- Metabolic hormones are integral regulators of female reproductive health and function.Bioscience reports · 2024Review
- Growth hormone reduces aneuploidy and improves oocytes quality by JAK2-MAPK3/1 pathway in aged mice.Journal of translational medicine · 2023Article
- Effect of growth hormone cotreatment in sub-fertile women ≥ 40 years: A Meta-analysis.Reproduction & fertility · 2023Article
- The Advantage of Growth Hormone Alone as an Adjuvant Therapy in Advanced Age and BMI ≥ 24 kg/mJournal of clinical medicine · 2023Article
- Calcium ionophore improves embryonic development and pregnancy outcomes in patients with previous developmental problems in ICSI cycles.BMC pregnancy and childbirth · 2022Article
- Effect of maternal sleep on embryonic development.Scientific reports · 2022Observational
- Impact of Follicle Stimulating Hormone Receptor (FSHR) Polymorphism on the Efficiency of Co-Treatment with Growth Hormone in a Group of Infertile Women from Romania.Diagnostics (Basel, Switzerland) · 2022Article
- The Clinical Application of Growth Hormone and Its Biological and Molecular Mechanisms in Assisted Reproduction.International journal of molecular sciences · 2022Review
- Clinical predictors of embryo quality among women of advanced age receiving intracytoplasmic sperm injection cycles in Malaysia: A cohort study.International journal of reproductive biomedicine · 2022Article
- Growth hormone in fertility and infertility: Mechanisms of action and clinical applications.Frontiers in endocrinology · 2022Review
- Effects of growth hormone co-treatment on in vitro fertilization outcomes in women with expected normal ovarian responseTurkish journal of obstetrics and gynecology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundMany studies have demonstrated the benefits of the addition of growth hormone (GH) to the controlled ovarian stimulation protocol in vitro fertilization (IVF) cycles in poor-respond patients, but the effect of GH on patients with poor embryonic development remain unclear. This paper was designed to investigate the efficacy of GH co-treatment during IVF for the patients with poor embryonic development.
methodA randomized controlled trial including 158 patients with poor embryo development was conducted between July 2017 and February 2019. One hundred and seven patients were randomized for GH treatment (GH group) and 51 patients for untreated (control group). The primary end-points were the clinical pregnancy and live birth rates in the two groups. The oocyte competence were assessed through calculating the mitochondrial DNA (mtDNA) copy number in corresponding cumulus granulosa cells (CGCs). Quantitative PCR were used for calculation of mtDNA copy number.
resultsRelative to the control group, GH co-treatment resulted in a significantly higher number of retrieved oocytes (10.29 ± 5.92 versus 8.16 ± 4.17, P = 0.023) and cleaved embryos (6.73 ± 4.25 versus 5.29 ± 3.23, P = 0.036). The implantation rate, clinical pregnancy rates per cycle, and live birth rate per cycle were higher in the GH group than in the control group (36.00% versus 17.86%, P = 0.005; 43.93% versus 19.61%, P = 0.005; 41.12% versus 17.65%, P = 0.006). CGCs of the GH group had significantly higher mtDNA copy numbers than CGCs of the control group (252 versus 204, P < 0.001).
conclusionsThese data provided further evidence to indicate that GH supplementation may support more live births during IVF, in patients with poor embryonic development. It also appears that oocytes generated under GH co-treatment have a better developmental competence.
trial registrationChiCTR1900021992 posted March 19, 2019 (retrospectively registered).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.